ENDOCRINE PHARMACEUTICALS LIMITED

Company number 03005721 · Active

ENDOCRINE PHARMACEUTICALS LIMITED is a private limited company registered in TADLEY, United Kingdom, incorporated on 4 Jan 1995. Its registered activity is other research and experimental development on natural sciences and engineering. Its latest published accounts for the period ending 30 Jun 2026 show equity of −£111k, a result of −£12k. It has filed 7 sets of accounts. Our model estimates a 0.00 % probability that it becomes insolvent within 12 months, 0.0 times the average for active companies (low risk).

Insolvency risk, next 12 months

0.00 %
Low risk
Lowest riskHighest risk

Higher than 0 % of active companies in the United Kingdom. 0.0× the average annual insolvency rate (0.12 %).

Raises the risk

Equity (signed log)4.0×< -4.26854 · 0.47 % became insolvent
Employees3.1×3–8 · 0.36 % became insolvent
Loss2.7×1 · 0.31 % became insolvent
Loss two years running2.4×1 · 0.28 % became insolvent
Company age (years)2.3×≥ 22.502 · 0.27 % became insolvent
Negative equity2.3×1 · 0.27 % became insolvent

Lowers the risk

Accounts filed0.3×≥ 6 · 0.04 % became insolvent
Days since last period end0.6×< 246 · 0.06 % became insolvent
Region0.6×RG · 0.07 % became insolvent
Late filings0.8×0–1 · 0.09 % became insolvent
Accounts overdue0.8×0 · 0.09 % became insolvent

Each factor compares companies in the same group (for example the same age band) with the average. The score is a statistical estimate from public data (model AUC 0.99, trained 8 Nov 2026), not a credit rating. How it works.

Company details

Company number
03005721 · official register
Status
Active
Legal form
Private Limited Company
Incorporated
4 Jan 1995 (32 years)
Registered address
RG26 3TA TADLEY
Postcode area
Reading
Activity
72190 Other research and experimental development on natural sciences and engineering
Industry
Scientific research and development
Accounts overdue
No

Insolvency and register events

No insolvency or liquidation events on record.

Annual accounts GBP

Period endPublishedTurnoverResultEquityTotal assetsCurrent liabilitiesCashEmployees
30 Jun 202621 Oct 2026– −£12k−£111k– –£3913
30 Jun 202515 Sep 2025– −£11k−£99k– –£1,5213
30 Jun 202415 Aug 2024– −£8,526−£90k– –£5,1873
30 Jun 202315 Nov 2023– −£11k−£88k– –£2,1603
30 Jun 202215 Oct 2022– −£17k−£77k– –£6,5963
30 Jun 202115 Oct 2021– −£12k−£70k– –£8,8783
30 Jun 202015 Oct 2020– −£9,263−£68k– –£4,8113

As published. Small companies often file a balance sheet only, so turnover and result can be missing.

Similar companies in Reading

Questions about ENDOCRINE PHARMACEUTICALS LIMITED

What is the company number of ENDOCRINE PHARMACEUTICALS LIMITED?

ENDOCRINE PHARMACEUTICALS LIMITED is registered under company number 03005721 in the official register of United Kingdom. View it at the official register.

Is ENDOCRINE PHARMACEUTICALS LIMITED still active?

Yes. ENDOCRINE PHARMACEUTICALS LIMITED is registered as active (status: Active).

Has ENDOCRINE PHARMACEUTICALS LIMITED gone bankrupt or into insolvency?

No insolvency, bankruptcy or administration is recorded for ENDOCRINE PHARMACEUTICALS LIMITED in the official data.

How likely is ENDOCRINE PHARMACEUTICALS LIMITED to become insolvent?

Our model estimates a 0.00 % probability that ENDOCRINE PHARMACEUTICALS LIMITED becomes insolvent within the next 12 months (low risk). That is higher than 0 % of active companies in the United Kingdom.

When was ENDOCRINE PHARMACEUTICALS LIMITED founded?

ENDOCRINE PHARMACEUTICALS LIMITED was incorporated on 4 Jan 1995.

Where is ENDOCRINE PHARMACEUTICALS LIMITED registered?

ENDOCRINE PHARMACEUTICALS LIMITED's registered address is in RG26 3TA TADLEY (Reading), United Kingdom.

What do the latest accounts of ENDOCRINE PHARMACEUTICALS LIMITED show?

The latest published accounts (period ending 30 Jun 2026) show equity of −£111k, a result of −£12k, 3 employees.

Data: Companies House – Free Company Data Product, Accounts Data Product, Public Data API (Contains public sector information licensed under the Open Government Licence v3.0.). Last updated 8 Nov 2026.